Paediatricians and other professionals working with families must understand the guidelines for managing CMV so that more families receive monitoring and support.
As the estimated costs for acute antiviral treatment are relatively minor, more research needs to be conducted to assess whether antiviral treatment can be effective in preventing or reducing the severity of other forms of impairment that develop as a consequence of cCMV.
There is evidence to show that the antiviral medicine valganciclovir is effective at reducing SNHL, as well as developmental delays in other neurocognitive functions, in the 24 months following birth.
Given that a high proportion of the cost burden is attributable to babies born without symptoms, who later develop neurodevelopmental impairments. More research into the benefits of this treatment in babies presenting with no symptoms may provide another avenue from which to target the cost burden of the virus. It is only through this that we will be able to bring the UK in line with other countries more advanced in managing CMV infection.